Immunological mechanisms in drug-induced liver injury

Drug-Induced Liver Disease, Second Edition

Volumn , Issue , 2007, Pages 115-123

  Thiele, Dwain L ^a  

^a UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84997933923     PISSN: None     EISSN: None     Source Type: Book    
DOI: None     Document Type: Chapter

References (80)

1. Liu ZX, Kaplowitz N. Immune-mediated drug-induced liver disease. Clin Liver Dis 2002; 6:755-74.
2. Seguin B, Uetrecht J. The danger hypothesis applied to idiosyncratic drug reactions. Curr Opin Allergy Clin Immunol 2003; 3:235-42.
3. Bissell DM, Gores GJ, Laskin DL, Hoofnagle JH. Drug-induced liver injury: mechanisms and test systems. Hepatology 2001; 33:1009-13.
4. Mieli-Vergani G, Vergani D, Tredger JM, Eddleston AL, Davis M, Williams R. Lymphocyte cytotoxicity to halothane altered hepatocytes in patients with severe hepatic necrosis following halothane anaesthesia. J Clin Lab Immunol 1980; 4:49-51.
5. Vergani D, Mieli-Vergani G, Alberti A, Neuberger J, Eddleston AL, Davis M, Williams R. Antibodies to the surface of halothane-altered rabbit hepatocytes in patients with severe halothane-associated hepatitis. N Engl J Med 1980; 303:66-71.
6. Bonierbale E, Valadon P, Pons C, Desfosses B, Dansette PM, Mansuy D. Opposite behaviors of reactive metabolites of tienilic acid and its isomer toward liver proteins: use of specific anti-tienilic acid- protein adduct antibodies and the possible relationship with different hepatotoxic effects of the two compounds. Chem Res Toxicol 1999; 12:286-96.
7. Liu ZX, Govindarajan S, Kaplowitz N. Innate immune system plays a critical role in determining the progression and severity of acetaminophen hepatotoxicity. Gastroenterology 2004; 127:1760-74.
8. Armeanu S, Bitzer M, Lauer UM, et al. Natural killer cell-mediated lysis of hepatoma cells via specific induction of NKG2D ligands by the histone deacetylase inhibitor sodium valproate. Cancer Res 2005; 65:6321-9.
9. Njoku DB, Greenberg RS, Bourdi M, Borkowf CB, Dake EM, Martin JL, Pohl LR. Autoantibodies associated with volatile anesthetic hepatitis found in the sera of a large cohort of pediatric anesthesiologists. Anesth Analg 2002; 94:243-9.
10. Rehermann B, Nascimbeni M. Immunology of hepatitis B virus and hepatitis C virus infection. Nat Rev Immunol 2005; 5:215-29.
11. Thiele DL. Autoimmune hepatitis. Clin Liver Dis 2005; 9:635-46.
12. Wagner M, Trauner M. Transcriptional regulation of hepatobiliary transport systems in health and disease: implications for a rationale approach to the treatment of intrahepatic cholestasis. Ann Hepatol 2005; 4:77-99.
13. Geier A, Dietrich CG, Voigt S, et al. Cytokine-dependent regulation of hepatic organic anion transporter gene transactivators in mouse liver. Am J Physiol Gastrointest Liver Physiol 2005; 289:6831-41.
14. Higuchi H, Bronk SF, Takikawa Y, Werneburg N, Takimoto R, El-Deiry W, Gores GJ. The bile acid glycochenodeoxycholate induces trail-receptor 2/DR5 expression and apoptosis. J Biol Chem 2001; 276:38610-8.
15. Faubion WA, Guicciardi ME, Miyoshi H, et al. Toxic bile salts induce rodent hepatocyte apoptosis via direct activation of Fas. J Clin Invest 1999; 103:137-45.
16. Thimme R, Wieland S, Steiger C, Ghrayeb J, Reimann KA, Purcell RH, Chisari FV. CD8(+) T cells mediate viral clearance and disease pathogenesis during acute hepatitis B virus infection. J Virol 2003; 77:68-76.
17. Chisari FV, Ferrari C. Hepatitis B virus immunopathogenesis. Annu Rev Immunol 1995; 13:29-60.
18. Ando K, Moriyama T, Guidotti LG, et al. Mechanisms of class I restricted immunopathology. A transgenic mouse model of fulminant hepatitis. J Exp Med 1993; 178:1541-54.
19. Kilgore NE, Ford ML, Margot CD, Jones DS, Reichardt P, Evavold BD. Defining the parameters necessary for T-cell recognition of ligands that vary in potency. Immunol Res 2004; 29:29-40.
20. Wang S, Chen L. T lymphocyte co-signaling pathways of the B7-CD28 family. Cell Mol Immunol 2004; 1:37-42.
21. Matzinger P. An innate sense of danger. Semin Immunol 1998; 10:399-415.
22. Chandok MR, Farber DL. Signaling control of memory T cell generation and function. Semin Immunol 2004; 16:285-93.
23. Bourdi M, Tinel M, Beaune PH, Pessayre D. Interactions of dihydralazine with cytochromes P4501A: a possible explanation for the appearance of anti-cytochrome P4501A2 autoantibodies. Mol Pharmacol 1994; 45:1287-95.
24. Manns MP, Obermayer-Straub P. Cytochromes P450 and uridine triphosphate-glucuronosyltransferases:model autoantigens to study drug-induced, virus-induced, and autoimmune liver disease. Hepatology 1997; 26:1054-66.
25. Maria VA, Victorino RM. Diagnostic value of specific T cell reactivity to drugs in 95 cases of drug induced liver injury. Gut 1997; 41:534-40.
26. Hofer T, Becker EW, Weigand K, Berg PA. Demonstration of sensitized lymphocytes to trimethoprim/sulfamethoxazole and ofloxacin in a patient with cholestatic hepatitis. J Hepatol 1992; 15:262-3.
27. Tsutsui H, Terano Y, Sakagami C, Hasegawa I, Mizoguchi Y, Morisawa S. Drug-specific T cells derived from patients with drug-induced allergic hepatitis. J Immunol 1992; 149:706-16.
28. Robin MA, Le Roy M, Descatoire V, Pessayre D. Plasma membrane cytochromes P450 as neoantigens and autoimmune targets in drug-induced hepatitis. J Hepatol 1997; 1:23-30.
29. Groothuis T, Neefjes J. The ins and outs of intracellular peptides and antigen presentation by MHC class I molecules. Curr Top Microbiol Immunol 2005; 300:127-48.
30. Eisenlohr LC, Rothstein JL. Antigen processing and presentation. Cancer Treat Res 2005; 123:3-36.
31. Pichler WJ. Modes of presentation of chemical neoantigens to the immune system. Toxicology 2002; 182:49-54.
32. Burkhart C, Britschgi M, Strasser I, Depta JP, von Greyerz S, Barnaba V, Pichler WJ. Non-covalent presentation of sulfamethoxazole to human CD4+T cells is independent of distinct human leucocyte antigen-bound peptides. Clin Exp Allergy 2002; 32:1635-43.
33. Orange JS, Ballas ZK. Natural killer cells in human health and disease. Clin Immunol 2006; 118:1-10.
34. O’Connor GM, Hart OM, Gardiner CM. Putting the natural killer cell in its place. Immunology 2006; 117:1-10.
35. Mercer JC, Ragin MJ, August A. Natural killer T cells: rapid responders controlling immunity and disease. Int J Biochem Cell Biol 2005; 37:1337-43.
36. Vermijlen D, Luo D, Froelich CJ, et al. Hepatic natural killer cells exclusively kill splenic/blood natural killer-resistant tumor cells by the perforin/granzyme pathway. J Leukoc Biol 2002; 72:668-76.
37. Ashton-Rickardt PG. The granule pathway of programmed cell death. Crit Rev Immunol 2005; 25:161-82.
38. Kagi D, Vignaux F, Ledermann B, et al. Fas and perforin pathways as major mechanisms of T cellmediated cytotoxicity. Science 1994; 265:528-30.
39. Braun MY, Lowin B, French L, Acha-Orbea H, Tschopp J. Cytotoxic T cells deficient in both functional fas ligand and perforin show residual cytolytic activity yet lose their capacity to induce lethal acute graft-versus-host disease. J Exp Med 1996; 183:657-61.
40. Russell JH, Ley TJ. Lymphocyte-mediated cytotoxicity [Review]. Annu Rev Immunol 2002; 20:323-70.
41. Podack ER, Young JD, Cohn ZA. Isolation and biochemical and functional characterization of perforin 1 from cytolytic T-cell granules. Proc Natl Acad Sci USA 1985; 82:8629-33.
42. Nakajima H, Park HL, Henkart PA. Synergistic roles of granzymes A and B in mediating target cell death by rat basophilic leukemia mast cell tumors also expressing cytolysin/perforin. J Exp Med 1995; 181:1037-46.
43. Motyka B, Korbutt G, Pinkoski MJ, et al. Mannose 6-phosphate/insulin-like growth factor II receptor is a death receptor for granzyme B during cytotoxic T cell-induced apoptosis. Cell 2000; 103:491-500.
44. Trapani JA, Sutton VR, Thia KY, et al. A clathrin/dynamin- and mannose-6-phosphate receptorindependent pathway for granzyme B-induced cell death. J Cell Biol 2003; 160:223-33.
45. Metkar SS, Wang B, Aguilar-Santelises M, et al. Cytotoxic cell granule-mediated apoptosis: perforin delivers granzyme B-serglycin complexes into target cells without plasma membrane pore formation. Immunity 2002; 16:417-28.
46. Kam CM, Hudig D, Powers JC. Granzymes (lymphocyte serine proteases): characterization with natural and synthetic substrates and inhibitors. Biochim Biophys Acta 2000; 1477:307-23.
47. Thornberry NA, Rano TA, Peterson EP, et al. A combinatorial approach defines specificities of members of the caspase family and granzyme B. Functional relationships established for key mediators of apoptosis. J Biol Chem 1997; 272:17907-11.
48. Darmon AJ, Nicholson DW, Bleackley RC. Activation of the apoptotic protease CPP32 by cytotoxic T-cell-derived granzyme B. Nature 1995; 377:446-8.
49. Martin SJ, Amarante-Mendes GP, Shi L, et al. The cytotoxic cell protease granzyme B initiates apoptosis in a cell-free system by proteolytic processing and activation of the ICE/CED-3 family protease, CPP32, via a novel two-step mechanism. EMBO J 1996; 15:2407-16.
50. Yang X, Stennicke HR, Wang B, et al. Granzyme B mimics apical caspases. Description of a unified pathway for trans-activation of executioner caspase-3 and -7. J Biol Chem 1998; 273:34278-83.
51. Talanian RV, Yang X, Turbov J, et al. Granule-mediated killing: pathways for granzyme B-initiated apoptosis. J Exp Med 1997; 186:1323-31.
52. Shi L, Chen G, MacDonald G, et al. Activation of an interleukin 1 converting enzyme-dependent apoptosis pathway by granzyme B. Proc Natl Acad Sci USA 1996; 93:11002-7.
53. Duan H, Orth K, Chinnaiyan AM, Poirier GG, Froelich CJ, He WW, Dixit VM. ICE-LAP6, a novel member of the ICE/Ced-3 gene family, is activated by the cytotoxic T cell protease granzyme B. J Biol Chem 1996; 271:16720-4.
54. Thomas DA, Du C, Xu M, Wang X, Ley TJ. DFF45/ICAD can be directly processed by granzyme B during the induction of apoptosis. Immunity 2000; 12:621-32.
55. Barry M, Heibein JA, Pinkoski MJ, Lee SF, Moyer RW, Green DR, Bleackley RC. Granzyme B shortcircuits the need for caspase 8 activity during granule-mediated cytotoxic T-lymphocyte killing by directly cleaving Bid. Mol Cell Biol 2000; 20:3781-94.
56. Sutton VR, Davis JE, Cancilla M, et al. Initiation of apoptosis by granzyme B requires direct cleavage of bid, but not direct granzyme B-mediated caspase activation. J Exp Med 2000; 192:1403-14.
57. Shresta S, MacIvor DM, Heusel JW, Russell JH, Ley TJ. Natural killer and lymphokine-activated killer cells require granzyme B for the rapid induction of apoptosis in susceptible target cells. Proc Natl Acad Sci USA 1995; 92:5679-83.
58. Shresta S, Graubert TA, Thomas DA, Raptis SZ, Ley TJ. Granzyme A initiates an alternative pathway for granule-mediated apoptosis. Immunity 1999; 10:595-605.
59. Beresford PJ, Zhang D, Oh DY, et al. Granzyme A activates an endoplasmic reticulum-associated caspase-independent nuclease to induce single-stranded DNA nicks. J Biol Chem 2001; 276:43285-93.
60. Johnson H, Scorrano L, Korsmeyer SJ, Ley TJ. Cell death induced by granzyme C. Blood 2003; 101:3093-101.
61. Kelly JM, Waterhouse NJ, Cretney E, Browne KA, Ellis S, Trapani JA, Smyth MJ. Granzyme M mediates a novel form of perforin-dependent cell death. J Biol Chem 2004; 279:22236-42.
62. Screpanti V, Wallin RP, Grandien A, Ljunggren HG. Impact of FASL-induced apoptosis in the elimination of tumor cells by NK cells. Mol Immunol 2005; 42:495-9.
63. Locksley RM, Killeen N, Lenardo MJ. The TNF and TNF receptor superfamilies: integrating mammalian biology. Cell 2001; 104:487-501.
64. Chen G, Goeddel DV. TNF-R1 signaling: a beautiful pathway. Science 2002; 296:1634-5.
65. Zender L, Hutker S, Mundt B, et al. NFkappaB-mediated upregulation of bcl-xl restrains TRAILmediated apoptosis in murine viral hepatitis. Hepatology 2005; 41:280-8.
66. Li S, Zhao Y, He X, et al. Relief of extrinsic pathway inhibition by the Bid-dependent mitochondrial release of Smac in Fas-mediated hepatocyte apoptosis. J Biol Chem 2002; 277:26912-20.
67. Bots M, Kolfschoten IG, Bres SA, et al. SPI-CI and SPI-6 cooperate in the protection from effector cellmediated cytotoxicity. Blood 2005; 105:1153-61.
68. Bird PI. Regulation of pro-apoptotic leucocyte granule serine proteinases by intracellular serpins. Immunol Cell Biol 1999; 77:47-57.
69. Barrie MB, Stout HW, Abougergi MS, Miller BC, Thiele DL. Antiviral cytokines induce hepatic expression of the granzyme B inhibitors, proteinase inhibitor 9 and serine proteinase inhibitor 6. J Immunol 2004; 172:6453-9.
70. Zheng SJ, Wang P, Tsabary G, Chen YH. Critical roles of TRAIL in hepatic cell death and hepatic inflammation. J Clin Invest 2004; 113:58-64.
71. Zhang HG, Xie J, Xu L, et al. Hepatic DR5 induces apoptosis and limits adenovirus gene therapy product expression in the liver. J Virol 2002; 76:5692-700.
72. Nakamoto Y, Guidotti LG, Pasquetto V, Schreiber RD, Chisari FV. Differential target cell sensitivity to CTL-activated death pathways in hepatitis B virus transgenic mice. J Immunol 1997; 158:5692-7 (erratum appears in J Immunol 1999 July 15; 163(2):1092).
73. Tay CH, Welsh RM. Distinct organ-dependent mechanisms for the control of murine cytomegalovirus infection by natural killer cells. J Virol 1997; 71:267-75.
74. Kafrouni MI, Brown GR, Thiele DL. Virally infected hepatocytes are resistant to perforin-dependent CTL effector mechanisms. J Immunol 2001; 167:1566-74.
75. Guicciardi ME, Deussing J, Miyoshi H, et al. Cathepsin B contributes to TNF-alpha-mediated hepatocyte apoptosis by promoting mitochondrial release of cytochrome c. J Clin Invest 2000; 106:1127-37.
76. Liu ZX, Govindarajan S, Okamoto S, Dennert G. Fas- and tumor necrosis factor receptor 1-dependent but not perforin-dependent pathways cause injury in livers infected with an adenovirus construct in mice. Hepatology 2000; 31:665-73.
77. Elkon KB, Liu CC, Gall JG, et al. Tumor necrosis factor alpha plays a central role in immune-mediated clearance of adenoviral vectors. Proc Natl Acad Sci USA 1997; 94:9814-9.
78. Abougergi MS, Gidner SJ, Spady DK, Miller BC, Thiele DL. Fas and TNFR1, but not cytolytic granuledependent mechanisms, mediate clearance of murine liver adenoviral infection. Hepatology 2005; 41:97-105.
79. Chirmule N, Moscioni AD, Qian Y, Qian R, Chen Y, Wilson JM. Fas-Fas ligand interactions play a major role in effector functions of cytotoxic T lymphocytes after adenovirus vector-mediated gene transfer. Hum Gene Ther 1999; 10:259-69.
80. Ogasawara J, Watanabe-Fukunaga R, Adachi M, et al. Lethal effect of the anti-Fas antibody in mice. Nature 1993; 364:806-9 (erratum appears in Nature 1993 October 7; 365(6446):568).